Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires 237,616 Shares

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi bought 237,616 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were bought at an average price of $1.00 per share, with a total value of $237,616.00. Following the purchase, the chief executive officer owned 4,793,684 shares in the company, valued at $4,793,684. The trade was a 5.22% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ivor Elrifi also recently made the following trade(s):

• On Tuesday, August 4th, Ivor Elrifi bought 83,807 shares of Tiziana Life Sciences stock. The shares were bought at an average cost of $0.97 per share, with a total value of $81,292.79.
• On Monday, August 3rd, Ivor Elrifi purchased 667,000 shares of Tiziana Life Sciences stock. The stock was bought at an average price of $1.00 per share, for a total transaction of $667,000.00.

Tiziana Life Sciences Stock Up 3.5%

Tiziana Life Sciences stock traded up $0.04 during trading hours on Thursday, hitting $1.02. The company had a trading volume of 434,962 shares, compared to its average volume of 240,434. Tiziana Life Sciences Ltd has a one year low of $0.87 and a one year high of $2.53. The firm has a 50-day moving average of $1.15 and a 200 day moving average of $1.30.

Analyst Ratings Changes

Several research firms have recently commented on TLSA. Zacks Research raised Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 29th. Finally, Wall Street Zen lowered Tiziana Life Sciences from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce”.

Institutional Trading of Tiziana Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Zhang Financial LLC raised its position in shares of Tiziana Life Sciences by 12.0% in the first quarter. Zhang Financial LLC now owns 111,900 shares of the company’s stock valued at $131,000 after buying an additional 12,000 shares in the last quarter. Marshall Wace LLP grew its position in Tiziana Life Sciences by 5.2% during the fourth quarter. Marshall Wace LLP now owns 282,017 shares of the company’s stock worth $420,000 after buying an additional 14,005 shares in the last quarter. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences during the fourth quarter worth approximately $25,000. Cubist Systematic Strategies LLC bought a new position in Tiziana Life Sciences during the 1st quarter worth $25,000. Finally, HRT Financial LP bought a new position in Tiziana Life Sciences during the 4th quarter worth $36,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.